- Email: [email protected]
Join us at The Lancet Clinic
Comment
Frédéric Amant*, Thierry Van den Bosch, Ignace Vergote, Dirk Timmerman Department of Obstetrics and Gynaecology, University Hospitals KU Leuven, 3000 Leuven, Belgium (FA, TV, IV, DT); Center for Gynecologic Oncology Amsterdam, Antoni van Leeuwenhoek–The Netherlands Cancer Institute, Amsterdam, The Netherlands (FA); and Department of Obstetrics and Gynecology, Tienen Regional Hospital, Tienen, Belgium (TV) [email protected]
4 5 6
7
8
We declare no competing interests. 1 2
3
Bulun SE. Uterine fibroids. N Engl J Med 2013; 369: 1344–55. Abeler VM, Royne O, Thoresen S, Danielsen HE, Nesland JM, Kristensen GB. Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology 2009; 54: 355–64. Koivisto-Korander R, Martinsen JI, Weiderpass E, Leminen A, Pukkala E. Incidence of uterine leiomyosarcoma and endometrial stromal sarcoma in Nordic countries: results from NORDCAN and NOCCA databases. Maturitas 2012; 72: 56–60.
9
10
Amant F, Coosemans A, Debiec-Rychter , Timmerman D, Vergote I. Clinical management of uterine sarcomas. Lancet Oncol 2009; 10: 1188–98. Shah SH, Jagannathan JP, Krajewski K, O’Regan KN, George S, Ramaiya NH. Uterine sarcomas: then and now. AJR Am J Roentgenol 2012; 199: 213–23. US Food and Drug Administration. FDA discourages use of laparoscopic power morcellation for removal of uterus or uterine fibroids, April 17, 2014. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm393689.htm (accessed Jan 1, 2015). Exacoustos C, Romanini ME, Amadio A, et al. Can gray-scale and color Doppler sonography differentiate between uterine leiomyosarcoma and leiomyoma? J Clin Ultrasound 2007; 35: 449–57. Brölmann H, Tanos V, Grimbizis G, et al, for the European Society of Gynaecological Endoscopy (ESGE) steering committee on fibroid morcellation. Options on fibroid morcellation: a literature review. Gynecol Surg 2015; 12: 3–15. Van den Bosch T, Dueholm M, Leone FP, et al. Terms and definitions for describing myometrial pathology using ultrasonography. Ultrasound Obstet Gynecol 2015; 46: 284–98. Dover RW, Ferrier AJ, Torode HW. Sarcomas and the conservative management of uterine fibroids: a cause for concern? Aust N Z J Obstet Gynaecol 2000; 40: 308–12.
Join us at The Lancet Clinic
Published Online October 5, 2015 http://dx.doi.org/10.1016/ S1470-2045(15)00370-8 For The Lancet Clinic see http://www.thelancet.com/clinic
For The Lancet Commission on liver disease in the UK see http://www.thelancet.com/ commissions/crisis-of-liverdisease-in-the-uk For The Lancet Liver Campaign see http://www.thelancet.com/ campaigns/liver For The Lancet Oncology/ The Lancet Cancer Campaign see http://www.thelancet.com/ campaigns/cancer
1456
On Oct 5, 2015, we launch the first 45 disease-specific pages of a major new online initiative involving all Lancet journals that will bring together an overview Seminar and relevant Reviews, Clinical Series, Commissions, research, Case Reports, and Clinical Pictures. Over the next 18 months or so when The Lancet Clinic is complete, there will be online pages for 135 diseases, which we have identified by a combination of global burden of disease data and clinical practice needs. We hope that The Lancet Clinic will help practising doctors make better informed decisions that ultimately lead to better lives of people worldwide, and help others who want to educate or update themselves keep abreast of the evolving evidence base. Importantly, these pages will be updated at regular intervals. The authors of newly commissioned Seminars have agreed to provide regular summaries of important new evidence for 4 years. Individual clinical editors will pull together newly published material from across the Lancet journals and post links to these on the page regularly. In addition, we are continuing our regular editorial policies of commissioning more specialised Clinical Reviews and Series across The Lancet Group to provide a more focused and in-depth assessment for key diseases. And beyond providing knowledge and information, we want to encourage academic and practising clinicians to use this knowledge for advocacy and change. In 2014, The Lancet published the first Clinical Commission on liver disease in the UK and in February, 2015, we launched our first Clinical Campaign based on this
Commission. A Cancer Campaign as a joint effort between The Lancet and The Lancet Oncology followed in April. Clinical Campaigns aim to effect change based on data, knowledge, and expert interpretation in partnership with others. Further Clinical Commissions on asthma, hypertension, dementia, tuberculosis, traumatic brain injury, psychotherapy, chronic obstructive pulmonary disease, and others are underway across all Lancet journals. With these Clinical Commissions and Campaigns, we hope to extend our goal to publish the best science for better lives to being an active partner in using this science for actual change. Commissions and Campaigns will be part of the disease pages to encourage engagement and actions. The Lancet Clinic invites you to be part of this endeavour. *Sabine Kleinert, Richard Horton, Elena Becker-Barroso, Niall Boyce, David Collingridge, Justine Davies, Emma Grainger, Peter Hayward, John McConnell, Zoë Mullan, Lan-Lan Smith The Lancet, London EC2Y 5AS, UK (SK, RH); The Lancet Neurology, London, UK (EB-B); The Lancet Psychiatry, London, UK (NB); The Lancet Oncology, London, UK (DC); The Lancet Diabetes & Endocrinology, London, UK (JD); The Lancet Respiratory Medicine, London, UK (EG); The Lancet HIV, London, UK (PH); The Lancet Infectious Diseases, London, UK (JM); The Lancet Global Health, London, UK (ZM); and The Lancet Haematology, London, UK (L-LS) [email protected] Copyright © Kleinert et al. Open Access article distributed under the terms of CC BY.
www.thelancet.com/oncology Vol 16 November 2015
Frédéric Amant*, Thierry Van den Bosch, Ignace Vergote, Dirk Timmerman Department of Obstetrics and Gynaecology, University Hospitals KU Leuven, 3000 Leuven, Belgium (FA, TV, IV, DT); Center for Gynecologic Oncology Amsterdam, Antoni van Leeuwenhoek–The Netherlands Cancer Institute, Amsterdam, The Netherlands (FA); and Department of Obstetrics and Gynecology, Tienen Regional Hospital, Tienen, Belgium (TV) [email protected]
4 5 6
7
8
We declare no competing interests. 1 2
3
Bulun SE. Uterine fibroids. N Engl J Med 2013; 369: 1344–55. Abeler VM, Royne O, Thoresen S, Danielsen HE, Nesland JM, Kristensen GB. Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology 2009; 54: 355–64. Koivisto-Korander R, Martinsen JI, Weiderpass E, Leminen A, Pukkala E. Incidence of uterine leiomyosarcoma and endometrial stromal sarcoma in Nordic countries: results from NORDCAN and NOCCA databases. Maturitas 2012; 72: 56–60.
9
10
Amant F, Coosemans A, Debiec-Rychter , Timmerman D, Vergote I. Clinical management of uterine sarcomas. Lancet Oncol 2009; 10: 1188–98. Shah SH, Jagannathan JP, Krajewski K, O’Regan KN, George S, Ramaiya NH. Uterine sarcomas: then and now. AJR Am J Roentgenol 2012; 199: 213–23. US Food and Drug Administration. FDA discourages use of laparoscopic power morcellation for removal of uterus or uterine fibroids, April 17, 2014. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm393689.htm (accessed Jan 1, 2015). Exacoustos C, Romanini ME, Amadio A, et al. Can gray-scale and color Doppler sonography differentiate between uterine leiomyosarcoma and leiomyoma? J Clin Ultrasound 2007; 35: 449–57. Brölmann H, Tanos V, Grimbizis G, et al, for the European Society of Gynaecological Endoscopy (ESGE) steering committee on fibroid morcellation. Options on fibroid morcellation: a literature review. Gynecol Surg 2015; 12: 3–15. Van den Bosch T, Dueholm M, Leone FP, et al. Terms and definitions for describing myometrial pathology using ultrasonography. Ultrasound Obstet Gynecol 2015; 46: 284–98. Dover RW, Ferrier AJ, Torode HW. Sarcomas and the conservative management of uterine fibroids: a cause for concern? Aust N Z J Obstet Gynaecol 2000; 40: 308–12.
Join us at The Lancet Clinic
Published Online October 5, 2015 http://dx.doi.org/10.1016/ S1470-2045(15)00370-8 For The Lancet Clinic see http://www.thelancet.com/clinic
For The Lancet Commission on liver disease in the UK see http://www.thelancet.com/ commissions/crisis-of-liverdisease-in-the-uk For The Lancet Liver Campaign see http://www.thelancet.com/ campaigns/liver For The Lancet Oncology/ The Lancet Cancer Campaign see http://www.thelancet.com/ campaigns/cancer
1456
On Oct 5, 2015, we launch the first 45 disease-specific pages of a major new online initiative involving all Lancet journals that will bring together an overview Seminar and relevant Reviews, Clinical Series, Commissions, research, Case Reports, and Clinical Pictures. Over the next 18 months or so when The Lancet Clinic is complete, there will be online pages for 135 diseases, which we have identified by a combination of global burden of disease data and clinical practice needs. We hope that The Lancet Clinic will help practising doctors make better informed decisions that ultimately lead to better lives of people worldwide, and help others who want to educate or update themselves keep abreast of the evolving evidence base. Importantly, these pages will be updated at regular intervals. The authors of newly commissioned Seminars have agreed to provide regular summaries of important new evidence for 4 years. Individual clinical editors will pull together newly published material from across the Lancet journals and post links to these on the page regularly. In addition, we are continuing our regular editorial policies of commissioning more specialised Clinical Reviews and Series across The Lancet Group to provide a more focused and in-depth assessment for key diseases. And beyond providing knowledge and information, we want to encourage academic and practising clinicians to use this knowledge for advocacy and change. In 2014, The Lancet published the first Clinical Commission on liver disease in the UK and in February, 2015, we launched our first Clinical Campaign based on this
Commission. A Cancer Campaign as a joint effort between The Lancet and The Lancet Oncology followed in April. Clinical Campaigns aim to effect change based on data, knowledge, and expert interpretation in partnership with others. Further Clinical Commissions on asthma, hypertension, dementia, tuberculosis, traumatic brain injury, psychotherapy, chronic obstructive pulmonary disease, and others are underway across all Lancet journals. With these Clinical Commissions and Campaigns, we hope to extend our goal to publish the best science for better lives to being an active partner in using this science for actual change. Commissions and Campaigns will be part of the disease pages to encourage engagement and actions. The Lancet Clinic invites you to be part of this endeavour. *Sabine Kleinert, Richard Horton, Elena Becker-Barroso, Niall Boyce, David Collingridge, Justine Davies, Emma Grainger, Peter Hayward, John McConnell, Zoë Mullan, Lan-Lan Smith The Lancet, London EC2Y 5AS, UK (SK, RH); The Lancet Neurology, London, UK (EB-B); The Lancet Psychiatry, London, UK (NB); The Lancet Oncology, London, UK (DC); The Lancet Diabetes & Endocrinology, London, UK (JD); The Lancet Respiratory Medicine, London, UK (EG); The Lancet HIV, London, UK (PH); The Lancet Infectious Diseases, London, UK (JM); The Lancet Global Health, London, UK (ZM); and The Lancet Haematology, London, UK (L-LS) [email protected] Copyright © Kleinert et al. Open Access article distributed under the terms of CC BY.
www.thelancet.com/oncology Vol 16 November 2015